Evidence map›Paper›PMID 42460332›Full record

ArticleBiomedical optics express2026

High-sensitivity Raman spectroscopy for prostate cancer detection and tissue extraction guidance.

Max J Dooley, Hanlin Li, Irene Low, Mary L Christie, Morgan R Pokorny, Ariane Araquel-Lacamiento, Alex Porter, Kamran Zargar-Shoshtari, Claude Aguergaray

Abstract read
In one paragraph

Article in Biomedical optics express, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Max J DooleyDepartment of Physics, University of Auckland, 38 Princes Street, Auckland 1010, New Zealand.
Hanlin LiDepartment of Physics, University of Auckland, 38 Princes Street, Auckland 1010, New Zealand.
Irene LowCounties Manukau District Health Board, 100 Hospital Road, Auckland 2025, New Zealand.
Mary L ChristieCounties Manukau District Health Board, 100 Hospital Road, Auckland 2025, New Zealand.
Morgan R PokornyCounties Manukau District Health Board, 100 Hospital Road, Auckland 2025, New Zealand.
Ariane Araquel-LacamientoCounties Manukau District Health Board, 100 Hospital Road, Auckland 2025, New Zealand.
Alex PorterSui Generis Health, 2150 NorthWest Pkwy SE Suite S Marietta, GA 30067, , USA.
Kamran Zargar-ShoshtariCounties Manukau District Health Board, 100 Hospital Road, Auckland 2025, New Zealand.
Claude AguergarayDepartment of Physics, University of Auckland, 38 Princes Street, Auckland 1010, New Zealand.ORCID https://orcid.org/0000-0001-5300-9920

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study presents classification models trained to diagnose and grade prostate cancer using fresh prostate biopsies. We compare the performance of classification models with optimised sensitivity and specificity (standard models) with application-specific models designed to maximise sensitivity and negative predictive value (NPV). Standard models achieve 80% sensitivity and 81% specificity. Application-specific models, calibrated to 90% sensitivity and 95% NPV, are intended to provide clinicians with a tool they can use with confidence to support intraoperative decisions, specifically to improve tissue retention during biopsy procedures and to ensure clear surgical margins. To this end, we introduce a 5-layer algorithm that combines 5 application-specific models chosen for overall best performance. This algorithm can reduce the number of biopsy samples required for diagnosis by 47% while maintaining 90% sensitivity, 95% NPV, and 62% specificity. All models are independently validated using two large patient cohorts. These results support the targeted use of Raman spectroscopy for real-time tissue analysis in diagnostic and intraoperative settings. The technology's clinical value as a decision-support tool aligns with the shared goal of pathologists and urologists to reduce the number of prostate biopsy cores while maintaining high sensitivity for clinically significant cancer. Prior studies have improved biopsy efficiency, but their performance has been variable, and concerns remain regarding underdetection of significant disease, revealing the need for approaches that improve biopsy efficiency without increasing diagnostic risk. The technology described here provides a realistic solution for targeted biopsy guidance to support more precise and evidence-based clinical decisions.

Identifiers

PMID42460332
PMCPMC13372381

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.